Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY5R | Q15761 | 6/20 | 0.53 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.49 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.45 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.44 |
| ▸ | CCR5 | P51681 | 1/20 | 0.43 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | TFPI2 | P48307 | 1/20 | 0.41 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.41 |
| ▸ | MBTD1 | Q05BQ5 | 1/20 | 0.41 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | DRD2 | P14416 | 1/20 | 0.40 |
| ▸ | DRD4 | P21917 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19652188 | 0.85 | NOTUM (0.52) | NPY5RGPR119NOTUMMCHR1CHRM4 | |
| SCHEMBL19652214 | 0.83 | MAPT (0.41) | NPY5RMCHR1L3MBTL1 | |
| SCHEMBL19652212 | 0.83 | NPY5R (0.42) | NPY5RAAK1CCR5USP2L3MBTL1 | |
| SCHEMBL19658738 | 0.83 | NPY5R (0.56) | NPY5RGPR119NOTUMMCHR1USP2 | |
| SCHEMBL19652187 | 0.83 | NOTUM (0.56) | NOTUML3MBTL1 | |
| SCHEMBL19652216 | 0.82 | FFAR1 (0.43) | NPY5RGPR119AAK1CHRM4MBTD1 | |
| SCHEMBL13478916 | 0.79 | NPY5R (0.53) | NPY5RGPR119NOTUMCCR5MCHR1 | |
| SCHEMBL13588400 | 0.79 | SIGMAR1 (0.62) | CHRM4DRD2 | |
| SCHEMBL19652143 | 0.78 | TAF1 (0.51) | CCR5DRD4 | |
| SCHEMBL19652108 | 0.76 | TRPV1 (0.46) | GPR119AAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10258603-B2 | Therapeutic compounds and uses thereof | GENENTECH, INC. (US) | 2019-04-16 | — | — | US | disclosed |
| US-20170340604-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2017-11-30 | — | — | US | disclosed |
| US-20170340604-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2017-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10258603-B2 | Therapeutic compounds and uses thereof | BRD4, BRDT, BRD3 | NPY5R 1431/4885GPR119 988/4885NOTUM 2215/4885 |
| US-20170340604-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | BRD4, BRDT, BRD3 | NPY5R 1431/4885GPR119 988/4885NOTUM 2215/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.